NAMS

NewAmsterdam Pharma Company NV

Add to Watchlist

Advanced Chart

22.430

-0.35(-1.536%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

23.590

Open

23.360

VWAP

22.47

Vol

1.19M

Mkt Cap

2.52B

Low

21.550

Amount

26.81M

EV/EBITDA(TTM)

Total Shares

89.99M

1.71B

EV/OCF(TTM)

P/S(TTM)

48.18

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

9.03M

-29.12%

6.77M

-76.73%

1.82M

-20.27%

Estimates Revision

The market is revising Upward the revenue expectations for NewAmsterdam Pharma Company N.V. (NAMS) for FY2025, with the revenue forecasts being adjusted by 6.61% over the past three months. During the same period, the stock price has changed by 11.98%.

Revenue Estimates for FY2025

Revise Upward

+6.61%

In Past 3 Month

Stock Price

Go Up

+11.98%

In Past 3 Month

11 Analyst Rating

85.78% Upside

Wall Street analysts forecast NAMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAMS is 41.67 USD with a low forecast of 27.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

1 Hold

0 Sell

Strong Buy

85.78% Upside

Current: 22.430

Low

27.00

Averages

41.67

High

52.00

85.78% Upside

Current: 22.430

Low

27.00

Averages

41.67

High

52.00

Goldman Sachs

Neutral

initiated

$27

2025-07-17

Reason

Goldman Sachs

Price Target

$27

2025-07-17

initiated

Neutral

Reason

Goldman Sachs initiated coverage of NewAmsterdam Pharma with a Neutral rating and $27 price target. The firm sees the stock as range-bound with results from the Phase 3 PREVAIL cardiovascular outcomes trial for the company's lead candidate obicetrapib is not expected until late 2026. However, Goldman is "constructive" on obicetrapib's LDL-C lowering and other lipid effects.

Citi

initiated

$42

2025-06-18

Reason

Citi

Price Target

$42

2025-06-18

initiated

Reason

Citi initiated coverage of NewAmsterdam Pharma with a Buy rating and $42 price target. The LDL cholesterol lowering market is "large and with substantial remaining unmet need," the analyst tells investors in a research note. The firm says upwards of 75% of patients with atherosclerotic cardiovascular disease still need additional therapies to help reach their targeted LDL-C goal level, and the growth of the non-statin market has seen high double digit precent growth year-over-year since 2020. NewAmsterdam's obicetrapib aims to be a first-in-class agent that would be an add-on to patients on statins to help address LDL-C levels, and with potential to be used in combination therapy with ezetimibe for those who need additional lipid lowering, contends Citi.

Stifel

initiated

$44

2025-06-09

Reason

Stifel

Price Target

$44

2025-06-09

initiated

Reason

Stifel initiated coverage of NewAmsterdam Pharma with a Buy rating and $44 price target. NewAmsterdam sets up as "a unique, late-stage cardiovascular-focused company" with a near-term path to regulatory filings and a cardiovascular outcomes trial that "very likely differentiates obicetrapib" within the large, growing lipid-lowering market, the analyst tells investors. There is "a significant amount of data/literature" supporting that obicetrapib and the PREVAIL trial are "fundamentally different" and even with "conservative commercial assumptions per docs," the firm sees the potential for significant upside to shares.

Cantor Fitzgerald

initiated

$42

2025-06-04

Reason

Cantor Fitzgerald

Price Target

$42

2025-06-04

initiated

Reason

Cantor Fitzgerald initiated coverage of NewAmsterdam Pharma with an Overweight rating and $42 price target.

Needham

Serge Belanger

Strong Buy

Reiterates

$42

2025-04-08

Reason

Needham

Serge Belanger

Price Target

$42

2025-04-08

Reiterates

Strong Buy

Reason

Scotiabank

George Farmer

Buy

Maintains

$47 → $52

2025-02-27

Reason

Scotiabank

George Farmer

Price Target

$47 → $52

2025-02-27

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for NewAmsterdam Pharma Company NV (NAMS.O) is -11.44, compared to its 5-year average forward P/E of 3.20. For a more detailed relative valuation and DCF analysis to assess NewAmsterdam Pharma Company NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

3.20

Current PE

-11.44

Overvalued PE

35.48

Undervalued PE

-29.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.13

Current EV/EBITDA

-8.46

Overvalued EV/EBITDA

10.66

Undervalued EV/EBITDA

-4.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

160.38

Current PS

150.86

Overvalued PS

375.06

Undervalued PS

-54.30

Financials

Annual

Quarterly

FY2025Q1

YoY :

+112.56%

2.98M

Total Revenue

FY2025Q1

YoY :

+26.26%

-68.93M

Operating Profit

FY2025Q1

YoY :

-57.85%

-39.53M

Net Income after Tax

FY2025Q1

YoY :

-67.92%

-0.34

EPS - Diluted

FY2025Q1

YoY :

-33.65%

-36.48M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-87.54%

-298.54

FCF Margin - %

FY2025Q1

YoY :

-80.17%

-1.33K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

4.0M

USD

3-6

Months

3.1M

USD

6-9

Months

14.0M

USD

0-12

Months

979.9K

USD

Bought

0-3

236.8K

USD

Months

3-6

109.7K

USD

Months

6-9

0.0

USD

Months

0-12

98.7K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

425.0K

Volume

6-9

Months

2.7M

Volume

0-12

Months

0.0

Volume

Bought

0-3

305.5K

Volume

Months

3-6

1.9M

Volume

Months

6-9

8.3M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

4.0M

USD

3-6

Months

3.1M

USD

6-9

Months

14.0M

USD

0-12

Months

979.9K

USD

Bought

0-3

236.8K

USD

Months

3-6

109.7K

USD

Months

6-9

0.0

USD

Months

0-12

98.7K

USD

Months

NAMS News & Events

Events Timeline

2025-07-30 (ET)

2025-07-30

08:30:00

NewAmsterdam Pharma presents data from BROADWAY trial at AAIC

2025-06-09 (ET)

2025-06-09

07:14:48

NewAmsterdam Pharma announces topline data from BROADWAY clinical trial

2025-05-08 (ET)

2025-05-08

08:02:47

NewAmsterdam Pharma reports Q1 revenue $2.978M, consensus $1.46M

News

8.5

11:00 AMNewsfilter

Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund

9.0

07-30Newsfilter

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

2.0

07-09NASDAQ.COM

NAMS Makes Bullish Cross Above Critical Moving Average